Search

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more

Priority Points System

The Priority Points System is designed to recognize sponsors’ investment and continuous support for EHA activities, and are allocated for each sponsorship program and/or item.

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma

EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.

Read more

EHA-ISHBT Hematology Tutorial on Hematological Disorders

Dates: February 28-29, 2020
Location: Chandigarh, India
Chairs: N Varma, P Malhotra, J Gribben

Organized by: European Hematology Association (EHA) & Indian Society of Hematology and Blood Transfusion (ISHBT)

EHA will join ISHBT for a fourth time to organize the EHA-ISHBT Hematology Tutorial, this time in Chandigargh,…

Read more